$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
The third "broad-spectrum anti-cancer drug" entrectinib is launched!
2025-10-19 11:44:20
Check Details
What are the dosage and precautions of entrectinib? Does entrectinib have any side effects?
2025-10-19 11:44:20
Check Details
Is erlotinib available in the country? How much does a box of erlotinib cost after medical insurance
2025-10-19 11:44:20
Check Details
How many times a day should I take gefitinib (Iressa)? What is the therapeutic effect of gefitinib
2025-10-19 11:44:20
Check Details
Sotoracib (AMG510) is now on the market~
2025-10-19 11:44:20
Check Details
Amg510 (sotorasiib) for the treatment of KRAS-G12C mutated non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Sotoracib (AMG510) is launched! Patient: High cost performance
2025-10-19 11:44:20
Check Details
Tepotinib, the world's first targeted drug for METex14 mutated lung cancer, was approved in Europe
2025-10-19 11:44:20
Check Details
The FDA announced that Rybrevant, the first targeted drug for lung cancer EGFR20ins, has been approved for marketing!
2025-10-19 11:44:20
Check Details
Where can I buy Rybrevant, a targeted therapy for lung cancer (NSCLC)? Are the side effects serious?
2025-10-19 11:44:20
Check Details
40 cigarettes a day can cause cerebral infarction! Smoking may cause these 3 serious diseases to come to you
2025-10-19 11:44:20
Check Details
Lumakras is approved in the United States to treat KRAS-G12C mutated non-small cell lung cancer (NSCLC)!
2025-10-19 11:44:20
Check Details
1
2
...
3981
3982
3983
3984
3985
3986
3987
...
4163
4164
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Weight Gain and Edema Management, Monitoring of Repotrectinib (Augtyro) During Treatment
2
How to Take Tucatinib (Tukysa): Dosing Schedule, Combination Use & Missed Dose Guidance
3
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
4
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
5
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
6
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
7
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
8
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
9
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
10
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
11
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
12
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data